Literature DB >> 23676986

Role of plasma kallikrein in diabetes and metabolism.

E P Feener1, Q Zhou, W Fickweiler.   

Abstract

Plasma kallikrein (PK) is a serine protease generated from plasma prekallikrein, an abundant circulating zymogen expressed by the Klkb1 gene. The physiological actions of PK have been primarily attributed to its production of bradykinin and activation of coagulation factor XII, which promotes inflammation and the intrinsic coagulation pathway. Recent genetic, molecular, and pharmacological studies of PK have provided further insight into its role in physiology and disease. Genetic analyses have revealed common Klkb1 variants that are association with blood metabolite levels, hypertension, and coagulation. Characterisation of animal models with Klkb1 deficiency and PK inhibition have demonstrated effects on inflammation, vascular function, blood pressure regulation, thrombosis, haemostasis, and metabolism. These reports have also identified a host of PK substrates and interactions, which suggest an expanded physiological role for this protease beyond the bradykinin system and coagulation. The review summarises the mechanisms that contribute to PK activation and its emerging role in diabetes and metabolism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23676986      PMCID: PMC3757113          DOI: 10.1160/TH13-02-0179

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  90 in total

1.  Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa.

Authors:  P E J Van Der Meijden; M Van Schilfgaarde; R Van Oerle; T Renné; H ten Cate; H M H Spronk
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

2.  A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation.

Authors:  S Selvarajan; L R Lund; T Takeuchi; C S Craik; Z Werb
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

3.  Increased levels of platelet-derived microparticles in patients with diabetic retinopathy.

Authors:  Nahoko Ogata; Masahito Imaizumi; Shosaku Nomura; Akira Shozu; Miwa Arichi; Masato Matsuoka; Miyo Matsumura
Journal:  Diabetes Res Clin Pract       Date:  2004-12-10       Impact factor: 5.602

4.  Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.

Authors:  Mark Peek; Paul Moran; Nerissa Mendoza; Dineli Wickramasinghe; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2002-10-07       Impact factor: 5.157

5.  Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats.

Authors:  H Nobukata; T Ishikawa; M Obata; Y Shibutani
Journal:  Metabolism       Date:  2000-07       Impact factor: 8.694

6.  Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator.

Authors:  Zia Shariat-Madar; Fakhri Mahdi; Alvin H Schmaier
Journal:  J Biol Chem       Date:  2002-02-05       Impact factor: 5.157

7.  Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome.

Authors:  Jia Liu; Ben-Bo Gao; Edward P Feener
Journal:  Transl Stroke Res       Date:  2010-08-28       Impact factor: 6.829

8.  Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome.

Authors:  Tetsuya Ueba; Takane Haze; Masaki Sugiyama; Mami Higuchi; Hitoshi Asayama; Yoshihiro Karitani; Tomofumi Nishikawa; Kohsuke Yamashita; Shuhei Nagami; Takeo Nakayama; Kazushi Kanatani; Shosaku Nomura
Journal:  Thromb Haemost       Date:  2008-08       Impact factor: 5.249

Review 9.  Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-03-11

10.  Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes.

Authors:  Carlos C Barros; Anderson Haro; Fernanda J V P Russo; Ines Schadock; Sandro S Almeida; Rosane A Ribeiro; Emerielle C Vanzela; Valeria P Lanzoni; Flavio C Barros; Milton R Moraes; Marcelo A Mori; Reury F P Bacurau; Martin Wurtele; Antônio C Boschero; Everardo M Carneiro; Michael Bader; Joao B Pesquero; Ronaldo C Araujo
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

View more
  19 in total

1.  Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Authors:  Zilun Hu; Pancras C Wong; Paul J Gilligan; Wei Han; Kumar B Pabbisetty; Jeffrey M Bozarth; Earl J Crain; Timothy Harper; Joseph M Luettgen; Joseph E Myers; Vidhyashankar Ramamurthy; Karen A Rossi; Steven Sheriff; Carol A Watson; Anzi Wei; Joanna J Zheng; Dietmar A Seiffert; Ruth R Wexler; Mimi L Quan
Journal:  ACS Med Chem Lett       Date:  2015-04-08       Impact factor: 4.345

Review 2.  The role of inflammation in diabetic eye disease.

Authors:  Marina Mesquida; Faye Drawnel; Sascha Fauser
Journal:  Semin Immunopathol       Date:  2019-06-07       Impact factor: 9.623

3.  Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.

Authors:  Takeshi Kita; Allen C Clermont; Nivetha Murugesan; Qunfang Zhou; Kimihiko Fujisawa; Tatsuro Ishibashi; Lloyd Paul Aiello; Edward P Feener
Journal:  Diabetes       Date:  2015-05-15       Impact factor: 9.461

4.  Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-03-04       Impact factor: 4.345

5.  Negatively charged silver nanoparticles cause retinal vascular permeability by activating plasma contact system and disrupting adherens junction.

Authors:  Yan-Min Long; Xing-Chen Zhao; Allen C Clermont; Qun-Fang Zhou; Qian Liu; Edward P Feener; Bing Yan; Gui-Bin Jiang
Journal:  Nanotoxicology       Date:  2015-09-23       Impact factor: 5.913

Review 6.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

7.  Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2017-07-11       Impact factor: 4.345

8.  Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP.

Authors:  Tatiana F Ottaiano; Sheila S Andrade; Cleide de Oliveira; Mariana C C Silva; Marcus V Buri; Maria A Juliano; Manoel J B C Girão; Misako U Sampaio; Alvin H Schmaier; Alexander Wlodawer; Francisco H A Maffei; Maria Luiza V Oliva
Journal:  Biochimie       Date:  2017-01-20       Impact factor: 4.079

9.  HDL and Surgery.

Authors:  Yue-Ming Peng; Jing-Song Ou
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

10.  Reactive dicarbonyl compounds cause Calcitonin Gene-Related Peptide release and synergize with inflammatory conditions in mouse skin and peritoneum.

Authors:  Anna K Becker; Andrea Auditore; Monika Pischetsrieder; Karl Messlinger; Thomas Fleming; Peter W Reeh; Susanne K Sauer
Journal:  J Biol Chem       Date:  2020-03-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.